The global bronchopulmonary dysplasia treatment market is entering a transformative era, set to grow from approximately USD 434.1 million in 2025 to USD 788.2 million by 2035, at a robust CAGR of 6.1%. This growth is primarily driven by the increasing incidence of premature births and the rising clinical urgency to manage chronic lung disease in neonates.

BPD, a severe respiratory condition afflicting premature infants, demands an evolving therapeutic approach that combines pharmacological innovation, advanced respiratory support, and regenerative medicine. As neonatal intensive care units (NICUs) globally report a rise in preterm deliveries, the need for bronchodilators, diuretics, corticosteroids, surfactant therapies, and newer interventions like nitric oxide and stem cell therapy is rapidly expanding.

From 2020 to 2024, the market observed consistent clinical adoption of diuretics and bronchodilators as the frontline pharmacologic choices for managing early-stage BPD. The clinical acceptance of nitric oxide therapy has notably grown, especially in Level III NICUs, enhancing oxygenation in severe cases. Meanwhile, surfactant therapy continues to be the bedrock of neonatal respiratory care, supplemented by burgeoning research into stem cell therapy as a future cornerstone of BPD treatment.

Hospital-based treatment protocols are increasingly favoring early interventions and multidisciplinary management. With post-discharge pediatric respiratory care gaining ground, healthcare systems are investing in integrated critical care pathways to support infants beyond the NICU. These trends are shaping the end-user landscape and catalyzing product innovation in neonatal drug delivery and diagnostic precision.

The United States remains the largest contributor to global BPD treatment revenues. The country’s advanced NICU infrastructure, broad access to surfactant and mechanical ventilation, and active clinical trials for biologics and stem cell therapies underpin its market dominance. A well-established guideline framework from bodies like the AAP and NIH ensures high adoption rates of evidence-based treatments. With a forecast CAGR of 3.8% (2025–2035), the U.S. market is expected to maintain steady growth supported by rising survival rates of extremely preterm infants.

India is projected to register the highest CAGR of 7.1% between 2025 and 2035. This accelerated growth is fueled by a high burden of preterm births, government-supported neonatal programs (e.g., FBNC), and increasing availability of CPAP, HFNC, and surfactant therapies in urban tertiary hospitals. NGOs and international donors are playing a pivotal role in expanding NICU access in rural areas, further elevating the market potential.

Japan, with a forecast CAGR of 4.5%, showcases one of the most technologically advanced neonatal healthcare systems. Despite a declining birth rate, the country maintains strong demand for BPD treatment through its emphasis on non-invasive respiratory support, digital lung function monitoring, and early weaning protocols. Government-funded research into growth factors and stem cell therapies enhances innovation in this mature market.

Germany’s BPD treatment market is characterized by its advanced perinatal care infrastructure and adherence to European respiratory care guidelines. With a CAGR of 4.3% forecast for the next decade, the country continues to invest in lung-protective ventilation strategies and pharmacologic optimization. Clinical uptake of minimally invasive surfactant therapy (MIST) and inhaled nitric oxide is increasing across tertiary NICUs.

In the UK, the BPD treatment market is projected to grow at a CAGR of 5.0% through 2035, thanks to strong NHS support, the National Neonatal Audit Programme (NNAP), and rising adoption of less invasive surfactant administration (LISA). Increased emphasis on post-discharge care, such as home oxygen therapy and community-based pulmonary monitoring, also supports long-term patient outcomes and broadens the market scope.

The BPD treatment landscape is being revolutionized by emerging regenerative medicine strategies. Stem cell therapies and protein replacements are making inroads into clinical trials, offering hope for treatment-resistant cases. Concurrently, advances in surfactant formulations and inhalation delivery devices are improving clinical efficacy and convenience.

Leading market players such as Chiesi Farmaceutici S.p.A., AbbVie Inc., Medtronic plc, Merck & Co., Philips Healthcare, and Drägerwerk AG are at the forefront of this transformation. These companies are actively investing in pipeline expansion, clinical trials, and strategic collaborations to strengthen their market footprint.

By End User:

By Region:

• East Asia
• South Asia & Pacific
• Middle East & Africa

Advantage Healthcare Insights to Outpace Competitors! https://www.futuremarketinsights.com/industry-analysis/therapy-area

Future Outlook

The next decade is expected to usher in a new era of personalized neonatal respiratory care. With predictive diagnostics, patient-specific drug regimens, and AI-powered monitoring systems on the rise, the global BPD treatment market is on a path of clinical and commercial evolution. Strategic investments in research, public health policy alignment, and cross-sector collaboration will be essential to meet the rising care demands of premature infants worldwide.

As stakeholders embrace innovation and standardization, the market is not only addressing unmet clinical needs but also shaping the future of neonatal intensive care. From urban hospitals to rural clinics, the race to improve survival and quality of life for premature infants is laying the foundation for a resilient and inclusive BPD treatment ecosystem.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: [email protected]
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube